
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Indus is well-positioned in the generic drug market, with a strong presence in North America, Europe, Japan, Russia, and Israeli markets. Their innovative medicine portfolio and biosimilars in neurology and immunology add to their growth potential. With unique dosing profiles and a differentiated "double-whammy" mechanism targeting both IL-2 and IL-15, Teva may outperform competitors in the autoimmune treatment space and capture a $2.5 billion franchise. Upcoming catalysts in 2026, including topline data for vitiligo and celiac disease, could drive significant value for the company. Furthermore, Teva's track record of executing well on its Pivot to Growth plan and potential line of sight to 30% operating margin by 2027 make the stock a Buy rating.
Bears say
Teva Pharmaceutical Indus is facing a challenging market environment as the generic drug industry becomes increasingly fragmented and dominated by antipsychotics causing severe side effects. Despite the recent acquisition, Teva's portfolio and pipeline remain stagnant, and its success relies heavily on execution. Weak sales performance in the 1Q and lack of significant growth drivers beyond 2027 indicate a downward outlook for the stock.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares